Covidien (NYSE:COV) helped finance the buyout of a pair of small medical device companies in Brazil and China by pulling resources from is operations in the U.S. and Europe, CEO José Almeida told investors this morning at the J.P. Morgan Healthcare conference.
FDA OKs new trial for Edwards Lifesciences heart valve
Edwards Lifesciences (NYSE:EW) said it won an investigational device exemption from the FDA to run a clinical trial of its Sapien 3 replacement heart valve in intermediate-risk patients.
Volcano lowers 2014 guidance, shares slide
St. Jude Medical beats guidance with Q4 prelims
MassDevice.com +3 | The top 3 med-tech stories for Jan. 10, 2014
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
AtriCure’s Q4 prelims send shares up
AngioDynamics swings to Q2 losses, but shares rise on earnings beat
AngioDynamics (NSDQ:ANGO) shares are up a tad today after the medical device company beat Wall Street’s expectations with its fiscal 2nd-quarter earnings.